To assess the safety, clinical outcome, and adverse events in patients treated with intravenous tPA for acute stroke.
- Tissue plasminogen activator (Activase®)Drug
Intervention Desc: Thrombolytic
Prospective, multicenter study of 389 patients at 57 medical centers in the United States.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Time intervals between stroke symptom onset, hospital arrival, and treatment with tPA; pretreatment computed tomographic scan results, intracerebral hemorrhage, and major systemic bleeding. The modified Rankin Scale score was used to assess clinical outcomes at 30 days.|